Literature DB >> 12562684

The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1.

Damian J McColl1, Michael D Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12562684     DOI： 10.1093/jac/dkg109

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  3 in total

1.  Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.

Authors:  Kirsten L White; James M Chen; Nicolas A Margot; Terri Wrin; Christos J Petropoulos; Lisa K Naeger; S Swaminathan; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism.

Authors:  Atsuko Hachiya; Eiichi N Kodama; Matthew M Schuckmann; Karen A Kirby; Eleftherios Michailidis; Yasuko Sakagami; Shinichi Oka; Kamalendra Singh; Stefan G Sarafianos
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

3.  Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230.

Authors:  Saran Vardhanabhuti; David Katzenstein; John Bartlett; Nagalingeswaran Kumarasamy; Carole L Wallis
Journal:  Open Forum Infect Dis       Date:  2016-08-24       Impact factor: 3.835
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.